ProPublica’s analysis of Open Payments data found that “me-too drugs” were the most heavily promoted in last five months of 2013. These drugs are generally newer and compete with cheaper, existing therapies, thus the need for aggressive marketing and differentiation.
While analyzing the data, ProPublica found that drug companies had submitted data with errors ranging from typos to blank fields and incorrect payment categorizations. The data submissions are not checked by CMS, so Open Payments users may encounter missing data or ambiguous payment records. Representatives from the pharmaceutical industry anticipate that future data submissions will go more smoothly. CMS expects to release payments data covering the full year 2014 this June.